Item 1. | Security and Issuer |
(a) | Title of Class of Securities:
Common Stock, par value $0.001 per share |
(b) | Name of Issuer:
Acutus Medical, Inc. |
(c) | Address of Issuer's Principal Executive Offices:
2210 Faraday Ave., Suite 100, Carlsbad,
CALIFORNIA
, 92008. |
Item 1 Comment:
This Amendment No. 9 (this "Amendment") to Schedule 13D amends the Schedule 13D filed by (i) Deerfield Mgmt III, L.P. ("Deerfield Mgmt III"), (ii) Deerfield Private Design Fund III, L.P. ("Deerfield Private Design Fund III"), (iii) Deerfield Mgmt, L.P. ("Deerfield Mgmt"), (iv) Deerfield Partners, L.P. ("Deerfield Partners"), (v) Deerfield Management Company, L.P. ("Deerfield Management") and (vi) James E. Flynn, a natural person ("Flynn" and, collectively with Deerfield Mgmt III, Deerfield Private Design Fund III, Deerfield Mgmt, Deerfield Partners and Deerfield Management, the "Reporting Persons"), as amended by Amendment Nos. 1, 2, 3, 4, 5, 6, 7 and 8 thereto (as previously amended, the "Schedule 13D"), with respect to the common stock of Acutus Medical, Inc (the "Company"). Deerfield Private Design Fund III and Deerfield Partners are collectively referred to herein as the "Deerfield Funds". Except as otherwise described herein, the information contained in the Schedule 13D remains in effect. Capitalized terms used but not otherwise defined in this Amendment have the meanings ascribed to them in the Schedule 13D. |
Item 4. | Purpose of Transaction |
| Item 4 of the Schedule 13D is hereby amended to add the following:
Following the execution of Amendment No. 5, the Company has (1) filed with the SEC on January 24, 2025, the Form 15 to effect a termination of the registration of the Company's securities under Section 12(g) of the Exchange Act and (2) paid on January 27, 2025, the warrant termination fee equal to $250,000 in the aggregate, in U.S. dollars. As a result, on January 27, 2025, all conditions for the effectiveness of Amendment No. 5 have been satiesfied and, consequently, all warrants beneficially owned by the Deerfield Funds have been cancelled. |
Item 5. | Interest in Securities of the Issuer |
(a) | Deerfield Mgmt III
Number of shares: 3,438,589 (comprised of shares of Common Stock and shares of Common Stock underlying Series A Common Equivalent Preferred Stock, in each case, held by Deerfield Private Design Fund III)
Percentage of shares: 5.42%*
Deerfield Private Design Fund III
Number of shares: 3,438,589
Percentage of shares: 5.42%*
Deerfield Mgmt
Number of shares: 1,974,638 (comprised of shares of Common Stock and shares of Common Stock underlying Series A Common Equivalent Preferred Stock, in each case, held by Deerfield Partners)
Percentage of shares: 4.90%*
Deerfield Partners
Number of shares: 1,974,638
Percentage of shares: 4.90%*
Deerfield Management
Number of shares: 5,492,725 (comprised of shares of Common Stock and shares of Common Stock underlying Series A Common Equivalent Preferred Stock, in each case, held by Deerfield Private Design Fund III and Deerfield Partners, together with shares of Common Stock underlying vested stock options and restricted share units held by Andrew ElBardissi for the benefit and at the direction of Deerfield Management)
Percentage of shares: 9.10%*
Flynn
Number of shares: 5,492,725 (comprised of shares held by Deerfield Private Design Fund III and Deerfield Partners, together with shares and shares underlying vested stock options and restricted share units held by Andrew ElBardissi for the benefit and at the direction of Deerfield Management)
Percentage of shares: 9.10%*
*Percentage beneficial ownership reported herein reflects 29,912,305 shares of Common Stock outstanding as of November 8, 2024, as reported by the Company in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024. |
(b) | Deerfield Mgmt III
Sole power to vote or direct the vote: 0
Shared power to vote or direct the vote: 3,438,589
Sole power to dispose or to direct the disposition: 0
Shared power to dispose or direct the disposition: 3,438,589
Deerfield Private Design Fund III
Sole power to vote or direct the vote: 0
Shared power to vote or direct the vote: 3,438,589
Sole power to dispose or to direct the disposition: 0
Shared power to dispose or direct the disposition: 3,438,589
Deerfield Mgmt
Sole power to vote or direct the vote: 0
Shared power to vote or direct the vote: 1,974,638
Sole power to dispose or to direct the disposition: 0
Shared power to dispose or direct the disposition: 1,974,638
Deerfield Partners
Sole power to vote or direct the vote: 0
Shared power to vote or direct the vote: 1,974,638
Sole power to dispose or to direct the disposition: 0
Shared power to dispose or direct the disposition: 1,974,638
Deerfield Management
Sole power to vote or direct the vote: 0
Shared power to vote or direct the vote: 5,492,725
Sole power to dispose or to direct the disposition: 0
Shared power to dispose or direct the disposition: 5,492,725
Flynn
Sole power to vote or direct the vote: 0
Shared power to vote or direct the vote: 5,492,725
Sole power to dispose or to direct the disposition: 0
Shared power to dispose or direct the disposition: 5,492,725
Flynn is the managing member of the general partner of each of Deerfield Mgmt, Deerfield Mgmt III and Deerfield Management. Deerfield Mgmt III is the general partner of Deerfield Private Design Fund III and Deerfield Mgmt is the general partner of Deerfield Partners. Deerfield Management is the investment manager of the Deerfield Funds. Vested Stock options, restricted share units and shares of Common Stock held by Andrew ElBardissi, an employee of Deerfield Management and a director of the Company, are held for the benefit and at the direction of Deerfield Management. |
(c) | Except as set forth in Items 4 and 6 of this Schedule 13D, no Reporting Person has effected any transactions in the Common Stock during the past 60 days. |